|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.35 SEK | 0.00% |
|
+13.11% | -5.31% |
| 23/06 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 18/06 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 113.61Cr 12Cr 10Cr 9.49Cr 8.78Cr 17Cr 1.12TCr 17Cr 45Cr 551.23Cr 44Cr 43Cr 1.91TCr | P/E 2026 * |
-14.3x | P/E 2027 * | -28.1x |
|---|---|---|---|---|---|
| Enterprise Value | 111.86Cr 12Cr 10Cr 9.34Cr 8.64Cr 16Cr 1.11TCr 17Cr 44Cr 542.74Cr 43Cr 43Cr 1.88TCr | EV / Sales 2026 * |
8.06x | EV / Sales 2027 * | 54.9x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +0.23% | ||
| 1 week | +13.11% | ||
| Current month | +1.66% | ||
| 1 month | +55.07% | ||
| 3 months | +19.55% | ||
| 6 months | -5.93% | ||
| Current year | -5.31% |
| 1 week | 17.9 |  | 23.5 |
| 1 month | 7.05 | | 23.5 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 01/01/2014 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 01/03/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 15/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 20/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 20/03/2024 |
Sten Scheibye
BRD | Director/Board Member | 74 | 20/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/03 | Buy | Chairman | 2,750 | 0.0052% | ||
| 09/03 | Buy | Executive/Senior Manager | 1,500 | 0.0028% | ||
| 09/03 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +13.11% | +0.23% | -71.12% | 12Cr | |
| +0.09% | +0.25% | +54.65% | +169.19% | 1,08500Cr | |
| -1.63% | -1.50% | +65.79% | +62.70% | 62TCr | |
| -1.12% | -4.27% | +31.10% | +84.44% | 44TCr | |
| +1.12% | -0.50% | +28.86% | +27.77% | 33TCr | |
| -1.54% | -9.05% | +23.73% | +29.16% | 28TCr | |
| +0.79% | -2.10% | +26.24% | +46.00% | 28TCr | |
| +0.62% | -1.61% | -29.39% | -39.41% | 22TCr | |
| -1.19% | -2.81% | +22.63% | +66.30% | 20TCr | |
| -0.72% | +2.72% | +19.07% | +81.19% | 17TCr | |
| Average | -0.12% | -0.15% | +24.29% | +45.62% | 36.22TCr | |
| Weighted average by Cap. | +0.09% | -1.06% | +38.35% | +85.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14Cr 1.44Cr 1.26Cr 1.16Cr 1.07Cr 2.03Cr 137.09Cr 2.07Cr 5.44Cr 67Cr 5.39Cr 5.28Cr 233.19Cr | 2.12Cr 21.89L 19.15L 17.66L 16.34L 31.02L 21Cr 31.53L 82.91L 10Cr 82.19L 80.41L 36Cr |
| Net income | 5.22Cr 54.01L 47.24L 43.57L 40.31L 76.51L 52Cr 77.79L 2.05Cr 25Cr 2.03Cr 1.98Cr 88Cr | -2.6Cr -26.96L -23.58L -21.75L -20.12L -38.19L -26Cr -38.83L -1.02Cr -13Cr -1.01Cr -99.02L -44Cr |
| Net Debt | -1.75Cr -18.09L -15.83L -14.6L -13.51L -25.63L -17Cr -26.06L -68.52L -8.48Cr -67.92L -66.46L -29Cr | 2.49Cr 25.73L 22.51L 20.76L 19.21L 36.46L 25Cr 37.07L 97.45L 12Cr 96.6L 94.51L 42Cr |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | SEK 21.35 | 0.00% | 3,29,605 |
| 09/26/09 | SEK 21.35 | +10.39% | 4,22,177 |
| 08/26/08 | SEK 19.34 | +0.21% | 3,45,402 |
| 07/26/07 | SEK 19.30 | +0.42% | 3,66,957 |
| 06/26/06 | SEK 19.22 | +1.59% | 2,11,207 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
